WASHINGTON — Health secretary Robert F. Kennedy Jr. has repeatedly promised to root out industry influence from the Food and Drug Administration.
But the Trump administration’s injection of political priorities into the agency, which has long been shielded from such meddling, has opened new avenues for lobbying. The pharmaceutical industry is working to capitalize, according to 10 people, including lobbyists, advisers, FDA officials, and an executive involved in the efforts.
“The nature of the relationship is so drastically different now,” Michael Abrams, a managing partner at Numerof and Associates who works with pharmaceutical clients on regulatory requirements, said of the interactions between companies and the administration. Abrams said the new system, under Trump, makes discussions about FDA decisions that once would have been “heretical” the new norm.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
